Acrivastine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{drugbox |
{{Drugbox
| IUPAC_name       = (''E'')-3-{6-[(''E'')-1-(4-methylphenyl)-3-pyrrolidin-1-yl-<br>prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
| Verifiedfields = changed
| image             =
| verifiedrevid = 477241254
| CAS_number        = 87848-99-5
| IUPAC_name = (''E'')-3-{6-[(''E'')-1-(4-methylphenyl)-3-pyrrolidin-1-yl-<br>prop-1-enyl]pyridin-2-yl}prop-2-enoic acid
| ATC_prefix        = R06
| image =Acrivastine.png
| ATC_suffix        = AX18
| PubChem          = 5284514
| DrugBank          =
| C = 22 | H = 24 | N = 2 | O = 2
| molecular_weight  = 348.438 g/mol
| smiles            = CC1=CC=C(C=C1)C(=CCN2CCCC2)C3=CC=CC(=N3)C=CC(=O)O
| bioavailability  =
| protein_bound    =
| metabolism        =
| elimination_half-life = 1.5 hours
| excretion        = [[Kidney|Renal]]
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US          =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status      =
| routes_of_administration =
}}


{{SI}}
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|acrivastine}}
| MedlinePlus = a682619
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US = Rx-only
| routes_of_administration = oral


<!--Pharmacokinetic data-->
| elimination_half-life = 1.5 hours
| excretion = [[Kidney|Renal]]


==Overview==
<!--Identifiers-->
'''Acrivastine''' is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist [[antihistamine]] and works by blocking H1 histamine receptors.
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 87848-99-5
| ATC_prefix = R06
| ATC_suffix = AX18
| PubChem = 5284514
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4447574
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = A20F9XAI7W
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02760
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1224
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 83168


It is sold under the brand name ''Benadryl Allergy Relief'' in the U.K. by [[Pfizer]], not to be confused with ''Benadryl Once a Day'', which is [[cetirizine]] and is also sold by Pfizer in the U.K. 
<!--Chemical data-->
This drug is currently not available as a generic in the U.K. <ref>[http://forums.moneysavingexpert.com/showthread.html?t=441494 Cheapest hayfever remedies 2007], Money Saving expert, May 15th,2007</ref>
| C=22 | H=24 | N=2 | O=2
| molecular_weight = 348.438 g/mol
| smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3
| InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
| InChIKey = PWACSDKDOHSSQD-IUTFFREVBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N
}}
'''Acrivastine''' is a medication used for the treatment of allergies and [[hay fever]]. It is a second-generation [[H1 antagonist|H1-receptor antagonist]] [[antihistamine]] (like its base molecule [[triprolidine]]) and works by blocking [[Histamine H1 receptor]]s.


In the [[U.S.]], ''acrivastine'' is the active ingrediant in the ''Semprex'' brand. [[Semprex-D]] is also ''acrivastine'' based, but also contains a decongestant.
This non-sedating{{verify source|date=November 2014}} antihistamine is sold under the brand name Benadryl Allergy Relief in the [[United Kingdom]] by [[McNeil Laboratories]], not to be confused with Benadryl Once a Day, which is [[cetirizine]] and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand


===Pill Images===
In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a [[decongestant]], [[pseudoephedrine]]. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.<ref>[http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7627 SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule] U.S. [[National Library of Medicine]], National Institutes of Health, May 2008</ref>
{{TempDrugImages}}
{{PillImage|fileName=SEMPREX_NDC_522440404.jpg|drugName=SEMPREX|NDC=522440404|drugAuthor=Actient Pharmaceuticals, LLC|ingredients=ACRIVASTINE[ACRIVASTINE];PSEUDOEPHEDRINE HYDROCHLORIDE[PSEUDOEPHEDRINE]|pillImprint=404;SEMPREX;D|dosageValue=8|dosageUnit=mg|pillColor=Green|pillShape=Capsule|pillSize=16|pillScore=1}}
{{PillImage|fileName=Semprex-D_NDC_530140404.jpg|drugName=Semprex-D|NDC=530140404|drugAuthor=UCB, Inc.|ingredients=acrivastine[acrivastine];pseudoephedrine hydrochloride[pseudoephedrine]|pillImprint=404;SEMPREX-D|dosageValue=8|dosageUnit=mg|pillColor=Green;White|pillShape=Capsule|pillSize=16|pillScore=1}}


==Comparisons with other popular antihistamines==
Unlike [[cetirizine]] or [[loratadine]], the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.<ref>{{cite web |url=http://www.medicines.org.uk/EMC/pdfviewer.aspx?isAttachment=true&documentid=21852 |title=Benadryl Allergy Relief |work=electronic Medicines Compendium (eMC) |year=2014 |accessdate=4 July 2014}}</ref> Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.


==References==
==References==
<references/>
{{reflist|2}}


{{Antihistamines}}
{{Antihistamines}}
{{Histaminergics}}


[[Category:H1 receptor antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Pharmacology stubs]]
[[Category:Pyridines]]
 
[[Category:Pyrrolidines]]
[[da:Acrivastin]]
[[Category:Alkenes]]
[[sk:Acrivastin]]
[[Category:Drug]]
 
{{WH}}
 
{{WS}}

Revision as of 18:38, 10 April 2015

{{Drugbox

| Verifiedfields = changed | verifiedrevid = 477241254 | IUPAC_name = (E)-3-{6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-yl-
prop-1-enyl]pyridin-2-yl}prop-2-enoic acid | image =Acrivastine.png

| tradename = | Drugs.com = International Drug Names | MedlinePlus = a682619 | pregnancy_AU = | pregnancy_US = B | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | routes_of_administration = oral

| elimination_half-life = 1.5 hours | excretion = Renal

| CAS_number_Ref =  ☒N | CAS_number = 87848-99-5 | ATC_prefix = R06 | ATC_suffix = AX18 | PubChem = 5284514 | DrugBank_Ref =  ☑Y | ChemSpiderID_Ref =  ☑Y | ChemSpiderID = 4447574 | UNII_Ref =  ☑Y | UNII = A20F9XAI7W | KEGG_Ref =  ☑Y | KEGG = D02760 | ChEMBL_Ref =  ☑Y | ChEMBL = 1224 | ChEBI_Ref =  ☒N | ChEBI = 83168

| C=22 | H=24 | N=2 | O=2 | molecular_weight = 348.438 g/mol | smiles = O=C(O)\C=C\c3nc(\C(=C\CN1CCCC1)c2ccc(cc2)C)ccc3 | InChI = 1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | InChIKey = PWACSDKDOHSSQD-IUTFFREVBW | StdInChI_Ref =  ☑Y | StdInChI = 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ | StdInChIKey_Ref =  ☑Y | StdInChIKey = PWACSDKDOHSSQD-IUTFFREVSA-N }} Acrivastine is a medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine (like its base molecule triprolidine) and works by blocking Histamine H1 receptors.

This non-sedating[verification needed] antihistamine is sold under the brand name Benadryl Allergy Relief in the United Kingdom by McNeil Laboratories, not to be confused with Benadryl Once a Day, which is cetirizine and is also sold by McNeil in the UK. It is available as an over-the-counter medication in the UK, also offered with pseudoephedrine under the Benadryl brand

In the U.S., acrivastine is the active ingredient in the Semprex brand. Semprex-D is also acrivastine-based, but contains a decongestant, pseudoephedrine. Semprex-D is marketed in the U.S. by Actient Pharmaceuticals.[1]

Comparisons with other popular antihistamines

Unlike cetirizine or loratadine, the standard dosage of which is one tablet every day, a single acrivastine tablet may be taken up to three times a day.[2] Not to be taken by over 65's, pregnant women or people with compromised liver or kidney function.

References

  1. ↑ SEMPREX-D - acrivastine and pseudoephedrine hydrochloride capsule U.S. National Library of Medicine, National Institutes of Health, May 2008
  2. ↑ "Benadryl Allergy Relief". electronic Medicines Compendium (eMC). 2014. Retrieved 4 July 2014.
Retrieved from "https://www.wikidoc.org/index.php?title=Acrivastine&oldid=1086175"